-
Mashup Score: 0Breyanzi: CAR T-cell Therapy Gets Positive CHMP Opinion for R/R Large B-Cell Lymphoma Manali Kamdar MD - 12 month(s) ago
iFrame is not supported! Breyanzi: CAR T-cell Therapy Gets Positive CHMP Opinion for R/R Large B-Cell Lymphoma Manali Kamdar MD By Manali Kamdar, MD from University of Colorado In March of this year, Bristol Myers Squibb announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicin…
Source: oncologytube.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet
-
Mashup Score: 0Breyanzi CAR-T trials meet primary endpoints for follicular, mantle cell lymphomas - 12 month(s) ago
Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints by demonstrating meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent’s manufacturer. Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — commonly called liso-cel — is a CD19-directed chimeric antigen receptor T-cell
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Two clinical trials evaluating lisocabtagene maraleucel met their primary endpoints of meaningful overall response rates among adults with follicular or mantle cell lymphomas, according to the agent's manufacturer. #Breyanzi @bmsnews https://t.co/k0MYHWXt4P
-
-
Mashup Score: 0
A phase 1/phase 2 trial of lisocabtagene maraleucel for adults with advanced chronic lymphocytic leukemia or small lymphocytic lymphoma met its primary endpoint, according to the agent’s manufacturer. Lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) — a CD19-directed chimeric antigen receptor T-cell therapy — is approved for treatment of adults with relapsed or
Source: www.healio.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Breyanzi study meets complete response endpoint for leukemia, lymphoma subgroup. https://t.co/opM47pMEyh #Breyanzi @bmsnews #HemOnc #OncAlert #MedEd
-
-
Mashup Score: 0
Coverage from the Institute for Value-Based Medicine® session with Astera Cancer Care in Edison, New Jersey, held November 3, 2022.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
Breaking New Ground in Episodes of Care, Including CAR T-Cell Therapy @OneOncology @HorizonBCBSNJ #Breyanzi https://t.co/L4M0ABmb3p via @AJMC_Journal
-
-
Mashup Score: 16U.S. FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi®for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy - 2 year(s) ago
I n the pivotal Phase 3 TRANSFORM trial, single infusion of Breyanzi significantly outperformed the nearly 30-year standard of care with median event-free survival of 10.1 months vs. 2.3 months and a well-established safety profile Approval was also based on data from the Phase 2 PILOT study, the first and only company-sponsored study of a CAR T cell therapy in patients with primary refractory or…
Source: news.bms.comCategories: Hem/Oncs, Latest HeadlinesTweet-
[BREAKING] @US_FDA Approves Bristol Myers Squibb’s CAR T Cell Therapy Breyanzi® for Relapsed or Refractory Large B-cell Lymphoma After One Prior Therapy https://t.co/Y5j9ZYaKHx based on TRANSFORM: https://t.co/im40bWJmRj and PILOT: https://t.co/kjwIqssxIL #CARTcells #breyanzi
-
-
Mashup Score: 0Lymphoma Daily - 2 year(s) ago
Content directly from sources and does not necessarily reflect my views by Jason R Westin
Source: paper.liCategories: Hem/Oncs, Latest HeadlinesTweet-
The latest Lymphoma Daily! https://t.co/namZb5NGBY Thanks to @pghdad @cancerfax @The_Daily_World #insurance #breyanzi
-
-
Mashup Score: 0New CAR T-Cell Therapy Breyanzi Approved for R/R B-Cell Lymphoma - 3 year(s) ago
The FDA approved the CD19-directed chimeric antigen receptor T-cell immunotherapy lisocabtagene maraleucel (Breyanzi, Bristol Myers Squibb) for the treatment of adults with relapsed or refractory large B-cell lymphoma after two or more lines of systemic therapy.
Source: www.clinicaloncology.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
.@US_FDA approves CART T-cell immunotherapy #Breyanzi @bmsnews for relapsed or refractory large B-cell lymphoma. https://t.co/Gc5soRgkYd #fda #lymphoma
-
-
Mashup Score: 0New CAR-T for Aggressive B-Cell Lymphoma Wins FDA Nod - 3 year(s) ago
Lisocabtagene maraleucel approved for patients who failed two prior treatments
Source: www.medpagetoday.comCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
The FDA approved #Breyanzi, a chimeric antigen receptor (CAR) T-cell therapy, for treating relapsed or refractory non-Hodgkin #lymphoma. By @icingram. @LymphSM https://t.co/u6S6RoS4cp
-
-
Mashup Score: 1
After some setbacks and delays, the FDA approved Bristol Myers Squibb’s Breyanzi for certain lymphomas. It’s the third CAR T treatment to win the regulatory nod and the first under a new regenerative medicine designation.
Source: MedCity NewsCategories: General Medicine News, Latest HeadlinesTweet-
FDA approves #Breyanzi, a #cancer #immunotherapy that Bristol Myers Squibb added to its pipeline via its Celgene acquisition. It's the 3rd CAR-T therapy to win the FDA OK, and the 1st ever approval under the new RMAT designation @frankvinluan reports https://t.co/Oksxp2uL7T $BMY
-
-
Mashup Score: 0FDA Approves Less Toxic Liso-Cel in R/R Large B-Cell Lymphoma - 3 year(s) ago
A CAR T-cell therapy that promises fewer side effects, and possibly lower hospital costs, wins approval after lengthy delays.
Source: AJMCCategories: Hem/Onc News and Journals, Latest HeadlinesTweet-
FDA Approves Less Toxic Liso-Cel in R/R Large B-Cell Lymphoma $BMY #Breyanzi https://t.co/QsQJuoe8AP via @AJMC_Journal
-
Exciting news for the fight against R/R large B-cell lymphoma! Breyanzi CAR-T cell therapy has received a positive CHMP opinion. This means more treatment options for Pts who have exhausted other options. Watch Here: https://t.co/DhRagH1gXf @mana1981 @CUDenver #LBCL #Breyanzi https://t.co/XyKObOzKae